Hartford Funds Management Co LLC Buys 340 Shares of Eli Lilly and Company (NYSE:LLY)

Hartford Funds Management Co LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 23.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,802 shares of the company's stock after buying an additional 340 shares during the quarter. Eli Lilly and Company accounts for approximately 0.1% of Hartford Funds Management Co LLC's holdings, making the stock its 27th largest holding. Hartford Funds Management Co LLC's holdings in Eli Lilly and Company were worth $1,488,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in LLY. PFG Advisors raised its stake in shares of Eli Lilly and Company by 12.9% in the 1st quarter. PFG Advisors now owns 4,100 shares of the company's stock valued at $3,386,000 after purchasing an additional 468 shares during the period. Ignite Planners LLC increased its position in shares of Eli Lilly and Company by 3.7% in the first quarter. Ignite Planners LLC now owns 1,998 shares of the company's stock valued at $1,587,000 after acquiring an additional 71 shares during the last quarter. Obermeyer Wealth Partners increased its position in shares of Eli Lilly and Company by 5.1% in the first quarter. Obermeyer Wealth Partners now owns 16,696 shares of the company's stock valued at $13,789,000 after acquiring an additional 811 shares during the last quarter. Van Strum & Towne Inc. increased its position in shares of Eli Lilly and Company by 22.1% in the first quarter. Van Strum & Towne Inc. now owns 7,179 shares of the company's stock valued at $5,929,000 after acquiring an additional 1,300 shares during the last quarter. Finally, HighPoint Advisor Group LLC increased its position in shares of Eli Lilly and Company by 1.8% in the first quarter. HighPoint Advisor Group LLC now owns 19,074 shares of the company's stock valued at $16,885,000 after acquiring an additional 333 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.8%

Shares of LLY stock opened at $765.88 on Tuesday. The company has a 50 day moving average of $767.03 and a 200-day moving average of $800.17. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm has a market cap of $725.85 billion, a P/E ratio of 62.16, a PEG ratio of 1.12 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the previous year, the business earned $2.58 EPS. The company's revenue for the quarter was up 45.2% on a year-over-year basis. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analyst Ratings Changes

A number of research firms recently commented on LLY. Hsbc Global Res cut Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday, June 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Morgan Stanley restated an "overweight" rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.